Organovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research note released on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Trading Up 2.3 %

Shares of NASDAQ ONVO opened at $0.35 on Friday. The stock’s 50-day moving average is $0.39 and its 200 day moving average is $0.46. The stock has a market cap of $5.38 million, a price-to-earnings ratio of -0.33 and a beta of 0.54. Organovo has a 1-year low of $0.32 and a 1-year high of $1.74.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Friday, November 8th. The medical research company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.12. Organovo had a negative net margin of 12,176.70% and a negative return on equity of 249.28%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.04 million. On average, analysts forecast that Organovo will post -0.77 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.